Latest Breaking News On - Revised international staging system - Page 1 : comparemela.com

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma

The FDA has approved ide-cel (Abecma) for adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy.

Belantamab Mafodotin Plus Vd More Than Doubles PFS in Relapsed/Refractory Multiple Myeloma

Belantamab mafodotin plus bortezomib and dexamethasone improved PFS vs daratumumab plus bortezomib and dexamethasone in relapsed/refractory myeloma.

Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.

New Multiple Myeloma Staging Systems Outperform the Standard

Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages.

Gracell Biotechnologies Presents Updated Clinical Data From Fastcar-T GC012F Demonstrating Deep And Durable Responses In Newly Diagnosed Multiple Myel...